by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
We provide expertise in: Formulation development Oral formulations: • Capsules, • Tablets, • Solutions, emulsions, suspensions. Modified release oral formulations Sustained release - deliver steady levels of drug over 12 to 24 hours following a single dose. Pulsed release - deliver pulses of drug over 12 to 24 hours following a single dose. Modifed release - immediate release of some drug and delayed release of the balance. Delayed release - target drug to a specifc site particularly avoiding release in the stomach via enteric coating. Technical advice and proprietary technology to assist with oral formulation challenges including bioavailability, solubility and taste. Licensed to handle CII/S8 compounds and utilise chlorinated solvents and alcohols in the manufacturing process. Dermaceuticals: • Gels, • Creams and pastes, • Lotions. Manufacturing: • Clinical trial batches, • Pilot and commercial manufacturing scales, • FDA, TGA, MHRA, TPD approved site. Analytical methods development, transfer, testing and stability. Regulatory affairs support Flexible packaging options and worldwide distribution services. THE DIFFERENCE BETWEEN WHAT YOU'RE QUOTED AND CHARGED Mayne Pharma International* 1538 Main North Rd Salisbury South South Australia 5107, Australia Email: email@example.com Phone: +618 8209 2666 Fax: +618 8281 6998 *A wholly owned subsidiary of Hospira Inc., Lake Forest, Ill, USA. P08-1620/R1 mayne Have you been told your drug development project would cost $100,000 and take 6 months but cost $1 million and took a year? Get it right the first time! Speak to us at Mayne Pharma International* about our contract development and manufacturing services. We have over 3 decades of experience developing and manufacturing complex products for oral drug delivery. Now that's a bitter pill to swallow Biotech’s next big thing Local biotech inventions shine in the INNOVIC Inter- national Next Big Thing Awards – a global, annual award to find and showcase innovations that have the potential to become 'the next big thing'. Amongst 25 fnalists, Victorian inventor Micah Atkin was the overall winner for his hand held medical diagnostic system and Sydney company, Fermiscan, was the Social/Community Beneft Winner for its breast cancer test. Fermiscan Holdings Limited won the award for its Fermiscan Breast Cancer Test, a new test using synchrotron-generated x-ray diffraction to detect the presence of breast cancer. "Scalp hair samples are used to detect changes in the molecular structure," Fermiscan Holding's then Science and Innovation Manager, Dr Peter French said. "The test is safe, painless and suitable for women of all ages. At present young women only have breast self examination to identify abnormalities, while mammograms and ultrasound for women over 50 can be time consuming, painful and the results can be affected by breast density. "The Fermiscan Breast Cancer Test overcomes all of these problems." A specially designed slide holds the hair samples for transportation and exposure to the synchrotron x-rays. "One in eight women will develop breast cancer in their lifetime," she said. "Early detection is vitally important. The Fermiscan Breast Cancer Test simplifies the procedure and will overcome some women's reluctance to be tested". The synchrotron x-ray diffraction pattern clearly indicates a circular pattern in women with breast cancer. Victorian inventor Micah Atkin was announced the overall winner for his handheld medical diagnostic system, a low cost testing system built to enable anyone to perform laboratory quality tests quickly and easily. "Remote medical testing is now a simple matter," Mr Atkin said. "The system is the size of a mobile phone and the test strips about the size of a credit card. Most test results take about two minutes rather than hours in a laboratory. "The testing options are endless, but our first priority was to create a test for tuberculosis. This disease kills over two million people a year. Over 90 million tests are done annually, but the accuracy with the current century-old method of testing is less than 50 per cent." The handheld medical diagnostic system can do many other tests using the same technology platform. The system also has application in retail medical clinics that are opening up through- out Europe and the US, including in every Walmart store. INNOVIC is an independent, not-for-profit organisation that provides a range of practical commercialisation services and free seminars to help people with new ideas. INNOVIC assists over 2,000 innovators each year. Winners received over $60,000 in cash and prizes. www.innovic.com.au